͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | | | Many congratulations to Professor Sir Jack Cuzick who will receive the inaugural Outstanding Achievement in Cancer Prevention Research Award at the Cancer Prevention Research Conference in London today.
The award honours exceptional and sustained contributions to the field of prevention research, recognising a leader whose work has profoundly advanced understanding, implementation or innovation in cancer prevention.
Unanimously agreed by the 2025 conference’s Scientific Programme Committee – Sarah Blagden, Marc Gunter and Liz Jaffee – and the conference partners, the prize recognises Jack’s immense contribution to the field. His groundbreaking work includes breast cancer risk modelling, HPV testing, tamoxifen and most recently anastrozole’s approval for breast cancer prevention, providing a vital option for reducing incidence of this disease, improving lives and showcasing the value of prevention research.
Read about Jack’s career in his own words in this Cancer News for Researchers Q&A from the archives. |
| | |
|
|
|
|
|
Could you be a campaign ambassador? |
| Key decisions about cancer prevention, diagnosis and access to treatments lie in the hands of the government. Impactful change truly happens when we make an informed case to them - and who better to deliver that message than researchers themselves?
The role of a Campaigns Ambassador is varied, empowering and rewarding, a way to see real change that translates ground-breaking discoveries at lab benches to world leading change on the political benches.
As a campaigner, you’ll receive an induction, as well as ongoing training opportunities to make sure you're confident and able to excel in the role. It’s highly flexible and will help you develop important skills that are hugely valued in the workplace, such as communication, influencing and relationship building. |
| | |
|
|
|
Find out from our current campaigners, why you should get in involved |
| Victoria Wilson, Cancer Research UK campaign manager and Ryan Devlin, Scientific Officer at the Cancer Research UK Scotland Institute, share how researchers can turn their expertise and lived experience into real political influence.
From helping secure £300 million for radiotherapy funding to supporting the Tobacco and Vapes Bill, Cancer Research UK campaigners have already helped shape life-saving policy. |
| | |
|
|
|
| | | | | Taking a low, daily dose of aspirin works just as well as higher doses to prevent bowel cancer in people with Lynch syndrome, according to results from the Colorectal Adenoma/Carcinoma Prevention Programme 3 (CaPP3) trial.
Participants in the CaPP3 trial were treated with three different doses of aspirin – 75-100mg, 300mg or 600mg – a day over five years. The trial found that the lowest daily dose (known as baby aspirin) was just as effective at reducing bowel cancer risk, with fewer diagnoses across all three doses.
The CaPP3 team is now in talks with the British National Formulary to update the advice it gives on aspirin for use as a cancer prevention drug, making it easier for GPs to prescribe aspirin to people with Lynch syndrome.
Sir John Burn, lead investigator on the CaPP3 trial, is set to present the results at the Cancer Prevention Research Conference in London today. | | |
| | | | | | | Scientists at our Cambridge Institute, in collaboration with the Spanish National Cancer Research Centre (CNIO) and Cambridge-based start-up Tailor Bio, have developed a genomic test that predicts resistance to platinum, anthracycline and taxane chemotherapies.
The test uses chromosomal instability (CIN) signatures – patterns of DNA disruption found through whole-genome sequencing to identify patients unlikely to benefit from these treatments.
The study, led by Geoff Macintyre (CNIO and CSO at Tailor Bio), James Brenton and Ania Piskorz (Cancer Research UK Cambridge Institute), emulated a randomised controlled trial using data from 840 patients.
They have now begun work to further validate the test for use in the clinic and to develop tests for other targeted cancer therapies to see how widely the technology could be applied across different cancer types. | | |
|
|---|
|
|
|
|
Stay ahead with news from the cutting edge of translation |
| Cancer Research Horizons is excited to launch a new quarterly newsletter designed to keep the biotech, pharma and investor communities connected to the forefront of translational cancer research.
Each issue will feature expert insights, emerging trends and the latest updates across drug discovery, clinical trials, licensing, partnerships and investment. Readers will also get exclusive content and thought leadership from the innovators driving oncology forward. |
| | |
|
|
|
| | | | | | | | | 12:00-13:00, 16 July 2025 |
|
|---|
| | | | | | 12:00-13:00, 02 October 2025 |
|
|---|
| | | | | | 13:30-18:00, 28 October 2025 |
|
|---|
|
|
|
|
Registrations are now open for the second Data-driven cancer research conference |
| Building on the success of our sold-out 2024 inaugural event, the conference is expanding and will take place at the Edinburgh International Conference Centre from 24–26 February 2026.
Join us for a three-day programme exploring the future of data-enabled cancer research, highlighting the transformational role of emerging tools and technologies in advancing our understanding of cancer. Each day is dedicated to a specific theme:
Day 1 - Horizon scanning technologies with quantum sensing, quantum imaging and quantum computation as exemplars.
Day 2 - Revolutionising cancer research: the transformative role of AI.
Day 3 - Personalising cancer medicine: the power of health data.
This is a must-attend event for anyone working in cancer research, data science, bioinformatics, computational oncology, computer science, mathematics or statistics, including those working at the interface between these disciplines. |
| | |
|
|
|
Funding & research opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | | | | | | | | | | | | | | | Applications accepted year round25 December 2025 |
|
|---|
|
| | |
|
|
| | Together we are
beating cancer |
| | |
|---|
|
|
|
| | | You are playing a crucial role in helping us beat cancer, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|
